Sodium Alginate & Calcium Carbonate

This oral suspension belongs to the Suspensions segment of the gastrointestinal medicines category, functioning simultaneously as a mucosal protectant, a fast-acting physical barrier, and a conventional antacid—a synergistic combination that very few single formulations can achieve.

Unlike systemic gastroenterology drugs that require absorption and hepatic processing, this triple-molecule combination works entirely within the gastric environment. The immediate physical onset of action means patients experience relief within minutes of dosing, making it a commercially superior product for both OTC heartburn management and prescription GERD therapy.

For pharmaceutical marketing companies and B2B distributors building a high-yield Gastroenterology contract manufacturing India portfolio, this formulation represents one of the highest-demand, fastest-moving antacid suspensions in the market. Brands built on this formulation consistently see strong repeat prescription and retail reorder rates due to the product’s distinctive fast, physical mechanism.

Formulating a stable, clinically effective alginate suspension is technically demanding. The three actives in this product have fundamentally different physical properties: Sodium Alginate is a hydrophilic biopolymer, Sodium Bicarbonate is a water-soluble salt, and Calcium Carbonate is a dense, poorly soluble mineral. As a premier Sodium Alginate Suspension Manufacturer Baddi, we have perfected the art of combining these into a uniform, shelf-stable, palatable suspension.

• Rheologically Optimised Matrix: We rigorously control the viscosity of the syrupy base at multiple production checkpoints. The suspension is engineered to remain freely pourable at ambient temperature, yet instantly transition to a thick, buoyant gel raft upon contact with gastric acid.
• Anti-Sedimentation Formulation: Calcium Carbonate is a heavy insoluble mineral with a natural tendency to compact into dense sediment. Our excipient selection and high-shear homogenization protocol prevents this, ensuring that a single gentle shake fully redistributes the active particles before each dose.
• Advanced Taste-Masking: We neutralize the inherently saline, marine-derived base note of Sodium Alginate using premium Peppermint and Spearmint flavoring systems. This delivers a clean, cooling, palatable suspension that maximises patient compliance.
• pH-Buffered Vehicle: The liquid matrix is formulated within a strictly controlled pH range. If the vehicle drifts acidic during storage, the alginate begins to gel inside the bottle. Our pH control protocol guarantees the product remains a pourable liquid throughout its 24-month shelf life.

Manufactured and supplied from our third-party manufacturing facility in Himachal Pradesh, this suspension is formulated to the following DCGI-approved clinical indications:

• Gastroesophageal Reflux Disease (GERD): The primary indication. Chronic acid regurgitation into the oesophagus is directly countered by the floating alginate raft, which physically blocks the gastro-oesophageal junction.
• Heartburn & Post-Prandial Acid Regurgitation: Immediate soothing of the burning retrosternal sensation, particularly effective after meals and at bedtime, making it ideal for positioning as both a therapeutic and a lifestyle-management product.
• Functional Dyspepsia & Indigestion: Relief from bloating, upper abdominal discomfort, and gas associated with excess gastric acid production or impaired gastric motility.
• Hiatal Hernia & Reflux Oesophagitis: The physical raft mechanism provides symptomatic protection to the inflamed oesophageal mucosa by preventing repeated acid contact, allowing damaged tissue to heal.

This formulation requires careful dosage adherence and is widely prescribed across clinical settings.

Clinical Mechanism

This formulation works through an elegant combination of chemistry and physics:

1. Sodium Alginate (Raft Former): Upon contact with gastric acid (HCl), Sodium Alginate undergoes rapid ionic gelation—converting from a flowing polymer solution into a thick, cohesive viscous gel that floats to the gastro-oesophageal surface.
2. Sodium Bicarbonate (Rapid Antacid + CO₂ Generator): Sodium Bicarbonate reacts instantly with HCl to neutralize acid and release carbon dioxide gas. These CO₂ microbubbles become trapped within the alginate gel matrix, ensuring the raft remains buoyant.
3. Calcium Carbonate (Sustained Antacid + Raft Reinforcer): While Bicarbonate provides rapid neutralization, Calcium Carbonate delivers a sustained buffering effect. The calcium ions cross-link with the alginate polymer chains, forming ionic bridges that structurally reinforce the raft.

Manufacturing Integrity

• Homogenised Suspension Stability: The calcium carbonate particles must be permanently and uniformly dispersed within the alginate polymer matrix. We employ high-shear chilled-vessel homogenization to achieve this stable dispersion across both pilot and commercial batch scales.
• pH Preservation of the Vehicle: The most technically challenging aspect of manufacturing this GERD oral suspension 250mg manufacturer India product is maintaining the liquid vehicle in a pH range where the alginate polymer remains fully solubilised as a suspension, not gelled.

For pharmaceutical marketers, the commercial value of this suspension lies in its unique pharmacodynamic bioperformance:

• Zero Systemic Absorption Required: The entire therapeutic effect is local and physical. None of the three actives needs to be absorbed into the bloodstream. The pharmacokinetic concept of bioavailability is replaced by bioperformance—the efficiency with which the alginate converts to a stable raft in the stomach.
• Fastest Possible Onset: Because there is no absorption step or hepatic first-pass, patient relief begins within 3–5 minutes of administration—an onset profile that no systemic antacid can match.
• Prolonged Local Action (Up to 4 Hours): Unlike antacid tablets that dissolve and wash away in under 30 minutes, the calcium-reinforced raft remains mechanically intact at the gastric surface for up to 4 hours.
• Superior Safety Profile: The absence of systemic absorption creates a broad safety profile, appropriate for pregnant women, elderly patients on polypharmacy regimens, and those with hepatic impairment.
• Optimized Packaging: The 150ml and 200ml pack sizes are calibrated to the standard dosing regimen, providing an optimal cost-per-treatment ratio.

Saar Biotech offers comprehensive Contract Manufacturing Antacids services from our high-capacity liquid manufacturing block. If you are seeking a reliable pharma contract manufacturer antacid suspension India partner, our Baddi facility provides:

• Facility: Segregated, contamination-controlled liquid manufacturing block with fully automated high-speed filling and capping lines.
• Capacity: Scalable from introductory 10,000-unit private-label launches to high volume liquid suspension manufacturer Baddi deployments of 2,00,000+ units.
• Quality Lab: In-house GLP-certified analytical laboratories equipped with calibrated viscometers, pH meters, and Agilent HPLC systems.
• Turnaround: 30–45 working days for new manufacturing agreements; 20–25 working days for established partners on repeat orders.
• Packaging: Pharmaceutical-grade 150ml and 200ml amber PET bottles, precision measuring cups, and custom mono-cartons.
• Regulatory: Full Schedule M and DCGI compliance, and complete Batch Manufacturing Record (BMR) transparency.
• MOQ: 5,000–10,000 units per SKU, structured to support both new-brand market entry and large-scale supply.

1. Warehousing Conditions: Store sealed cartons in a cool, dry environment strictly below 30°C. Elevated ambient temperatures accelerate viscosity degradation in the alginate polymer.
2. Freeze Protection is Mandatory: This suspension absolutely must not be exposed to sub-zero temperatures. Freezing causes irreversible phase separation of the calcium carbonate particles from the alginate matrix.
3. End-User Labeling Instruction: All packaging must carry the “Shake Well Before Use” instruction prominently to ensure the dense calcium carbonate is fully resuspended before dosing.
4. Light Protection: Direct sunlight exposure degrades the flavoring system. Amber PET bottles and opaque mono-carton packaging provide adequate photo-protection.

As a leading Sodium Alginate antacid suspension WHO-GMP manufacturer India, every batch undergoes an exhaustive analytical testing battery:

• Viscosity & Rheological Profiling: The single most critical release test. We measure flow resistance to confirm the suspension is pourable yet highly reactive to gastric acid.
• HPLC & Titrimetric Assay (Label Claim Accuracy): Quantitative confirmation of Sodium Alginate, Sodium Bicarbonate, and Calcium Carbonate concentrations against the declared label claim (target: 95–105% IP specification).
• pH Mapping of Vehicle: Tested to confirm it remains within the pre-validated alkaline pH range that prevents premature in-bottle gelation.
• Microbial Limit Test (MLT): IP-mandated microbiological testing confirming the complete absence of specified pathogens and verifying total aerobic microbial count.
• Raft Formation Test: Functional testing that simulates the suspension’s performance in a simulated gastric acid environment, confirming raft integrity and acid neutralization capacity.
• Certificate of Analysis (COA): A comprehensive COA is issued alongside every B2B batch dispatch, ensuring your brand is perpetually audit-ready.

This physical-mechanism alginate raft suspension contract manufacturing product is exceptionally well-tolerated:

• Adverse Effects: Generally rare and mild. May include transient belching or flatulence (from carbon dioxide release), or occasional mild constipation.
• Contraindications: Contraindicated in patients with confirmed hypercalcemia, severe renal impairment, or uncontrolled hypertension. The sodium contribution requires prescriber evaluation for sodium-restricted patients.
• Drug Interactions: Clinically significant absorption interactions with tetracycline, fluoroquinolone antibiotics, iron supplements, and levothyroxine. A minimum 2-hour administration gap is required.
• Healthcare professionals should refer to the complete prescribing information for full safety data before dispensing.

For high-volume contract manufacturing agreements, third-party supply arrangements, or to request complete technical dossiers and pricing for Sodium Alginate, Bicarbonate & Calcium Carbonate Suspension, please use the B2B enquiry form below.